Phosphorothioate-stimulated uptake of siRNA by mammalian cells: a novel route for delivery.
The efficient delivery of biologically functional short interfering RNA (siRNA) in vivo remains a widely unresolved technical problem in therapeutic drug development. The repertoire of concepts for the cellular uptake of oligonucleotide-based tools and drugs has been extended by the mechanistically novel finding that phosphorothioate (PS)-modified single-stranded oligodeoxyribonucleotides (ON) promote the intracellular accumulation of naked extra-cellular siRNA in a variety of cell types. This mode of delivery gives rise to substantial intracellular amounts of siRNA, up to 10(4) siRNA molecules per cell. Conversely, the moderate biological effectiveness strongly indicates that intracellular release of siRNA from sub-cellular compartments where it seems to be trapped is a necessary step towards efficient target suppression. Here, we summarize key characteristics of the PS-stimulated cellular uptake of siRNA and describe concepts for the increase of intracellular delivery of biologically functional siRNA.
Detzer
Anke
A
Institut für Molekulare Medizin, Universität zu Lübeck and UK S-H, Campus Lübeck, Ratzeburger Allee 160, D-23538 Lübeck, Germany.
Sczakiel
Georg
G
D000818:Animals; D009946:Organothiophosphorus Compounds / Q000378:metabolism*; D034741:RNA, Small Interfering / Q000378:metabolism*
D009946:Organothiophosphorus Compounds; D034741:RNA, Small Interfering